Reference
Scottish Medicines Consortium. SMC advice: alogliptin (Vipidia); alogliptin plus metformin (Vipdomet); azelastine hydrochloride + fluticasone propionate (Dymista); brentuximab vedotin (Adcetris); capsaicin (Qutenza); dabigatran etexilate (Pradaxa); empagliflozin (Jardiance); fingolimod (Gilenya); golimumab (Simponi); lurasidone (Latuda); misoprostol (Mysodelle); posaconazole (Noxafil); simeprevir (Olysio); trastuzumab emtansine (Kadcyla). Internet Document : 13 Oct 2014. Available from: URL: http://www.scottishmedicines.org.uk/Home
Rights and permissions
About this article
Cite this article
SMC releases latest recommendations. PharmacoEcon Outcomes News 714, 36 (2014). https://doi.org/10.1007/s40274-014-1657-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1657-6